Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Total Current Assets
All assets expected to be converted to cash or used up within one year.
Aktis Oncology, Inc.NASDAQ: AKTS
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets of $543.94M in Q1 FY2026
Q1 FY2026 total current assets was $543.94M. Over 3 fiscal years it compounded at +20.2% a year.
Context
- Total current assets amounted to 94.3% of total assets at the end of Q1 FY2026.
- Total current assets increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 230.31M USD
- Year-over-year change
- -23.4%
- 3-year CAGR
- +20.2%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 230.31M | -23.4% |
| FY2024 | 2024-12-31 | 300.85M | +200.2% |
| FY2023 | 2023-12-31 | 100.2M | -24.4% |
| FY2022 | 2022-12-31 | 132.48M | — |
Total Current Assets vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 total current assets of $543.94M is the 3rd highest of the 6 companies compared; the peer median is $477.8M.
- Total current assets amounts to 94.3% of total assets for AKTS, versus a peer median of 93.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1B | +5.8% | +28.1% | 93.6% | |
| Mar 2026 | $619.14M | -27.7% | +19.4% | 94.9% | |
| Mar 2026 | $543.94M | — | +20.2% | 94.3% | |
| Sep 2026 | $477.8M | +70.7% | +207.8% | 94.5% | |
| Mar 2026 | $182.52M | +0.2% | -0.3% | 83.8% | |
| Mar 2026 | $118.5M | -11.9% | -8.7% | 86.1% | |
| Peer median (excluding AKTS) | $477.8M | +0.2% | +19.4% | 93.6% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.